MALT1 Inhibition as a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia by Blocking Notch1-Induced NF-κB Activation.
MALT1 Inhibition as a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia by Blocking Notch1-Induced NF-κB Activation.
复制标题
MALT1 抑制作为 T 细胞急性淋巴细胞白血病的治疗策略,通过阻断 Notch1 诱导的 NF-κ B 激活
DOI:
10.3389/fonc.2020.558339
复制
发表时间:
2020
影响因子:
4.7
通讯作者:
Niu M
中科院分区:
文献类型:
--
作者:
Wang R;Zhang H;Xu J;Zhang N;Pan T;Zhong X;Zhang H;Yin L;Yao Y;Wu Q;Li Z;Liu X;Xu K;Niu M
Current treatment of T-cell acute lymphoblastic leukemia (T-ALL) is primarily based on high-intensity combination chemotherapy, which has serious side effects. Therefore, developments of novel targeted therapeutics are urgently needed for treatment of T-ALL. In this study, we found that mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a novel promising therapeutic target for treatment of T-ALL. MALT1 inhibitor MI-2 significantly suppressed the cell growth, proliferation, and colony formation of T-ALL cells. Furthermore, MI-2 induced cell apoptosis of T-ALL via a mitochondrial-dependent pathway. In a T-ALL mouse model, MI-2 significantly reduced leukemic burden and prolonged the survival of leukemia-bearing mice. Mechanistically, MALT1 inhibition effectively blocked both baseline and Notch1-induced activation of nuclear factor κB pathway, which mediates T-ALL cell survival. In conclusion, our results highlight the potential role of MALT1 as an attractive target for treatment of T-ALL and support the potential of MI-2 or other MALT1 inhibitors to clinical trials in T-ALL.
登录
查看更多内容
影响因子:
5.2
作者:
Dos Santos NR;Ghezzo MN;da Silva RC;Fernandes MT
通讯作者:
Fernandes MT
影响因子:
9.7
作者:
Liu, Xueqing;Chen, Bi;Jiang, Handong
通讯作者:
Jiang, Handong
影响因子:
56.9
作者:
Weng, AP;Ferrando, AA;Aster, JC
通讯作者:
Aster, JC
影响因子:
6.5
作者:
Kuhlen, Michaela;Bleckmann, Kirsten;Chen-Santel, Christiane
通讯作者:
Chen-Santel, Christiane
影响因子:
64.5
作者:
ELLISEN, LW;BIRD, J;SKLAR, J
通讯作者:
SKLAR, J